Rybelsus (tablet) is FDA-approved to lower blood sugar levels in adults living with type 2 diabetes
Its central and gastrointestinal actions reduce caloric intake, meal size, and appetite drive
Mazdutide is already approved for both type 2 diabetes and obesity in China, and is being developed in other markets by its original developer Eli Lilly, Novo Nordisk's biggest rival in the GLP-1 category
Indirect Factors That May Influence Sexual Function Whilst Saxenda does not directly affect libido, several indirect factors associated with the medication and weight loss journey may influence sexual function: Gastrointestinal side effects : The most common adverse effects of Saxendanausea, vomiting, diarrhoea, and abdominal discomfortcan significantly impact overall wellbeing
This is a significant achievement, considering the challenges individuals with obesity face in shedding excess weight
Retatrutide dosage should be determined by a healthcare provider based on individual needs